Meeting Report

Biomarker Jeopardy

Presented by Sandra E. Kurtin,(1) PhD, ANP-C, AOCN®, Alyssa Henglefelt,(2) PharmD, BCOP, and Haleigh Mistry,(3) MS, PA-C

From (1)The University of Arizona Cancer Center, Phoenix, Arizona; (2)HonorHealth – Virginia G. Piper Cancer Care Network, Scottsdale, Arizona; (3)The University of Texas MD Anderson Cancer Center, Houston, Texas

Presenters’ disclosures of conflicts of interest are found at the end of this article.


J Adv Pract Oncol 2022;13(3):292–297 | https://doi.org/10.6004/jadpro.2022.13.3.22 | © 2022 Harborside™


  

ABSTRACT

In the popular Biomarker Jeopardy session, Sandra E. Kurtin, PhD, ANP-C, AOCN®, Alyssa Henglefelt, PharmD, BCOP, and Haleigh Mistry, MS, PA-C, paired biomarkers with tumor types for which their expression is most commonly used to determine targeted therapy, identified key assays used to measure common biomarkers, and discussed guidelines for biomarker testing.




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.